دالستراپیب
Sign in to saveAlso known as Dalcetrapib
Dalcetrapib (INN, development code JTT-705) is a CETP inhibitor which was originally being developed by F. Hoffmann–La Roche until May 2012. DalCor Pharmaceuticals licensed dalcetrapib as a potential pioneering precision medicine for patients with cardiovascular disease. By combining genetic and clinical insights into the development program, dalcetrapib is intended to reduce fatal and non-fatal myocardial infarction (MI) following a recent acute coronary syndrome (ACS) and deliver superior cardiovascular outcome in a specific genetic subset of patients. A companion diagnostic test, developed
Research
266 papers- Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib.Clinical pharmacokinetics · 2018
- Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome.European heart journal · 2022
- Dalcetrapib: a review of Phase II data.Expert opinion on investigational drugs · 2010
- Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans.Journal of lipid research · 2023
- Effects of dalcetrapib in patients with a recent acute coronary syndrome.The New England journal of medicine · 2012
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 389.239
Show 3 more facts
- chemical formula
- C₂₃H₃₅NO₂S
- canonical SMILES
- CCC(CC)CC1(CCCCC1)C(=O)NC2=CC=CC=C2SC(=O)C(C)C
- Commons category
- Dalcetrapib
Sources (2)
via Wikidata · CC0